HK1068886A1 - Indolinone derivatives useful as protein kinase inhibitors - Google Patents

Indolinone derivatives useful as protein kinase inhibitors

Info

Publication number
HK1068886A1
HK1068886A1 HK05101511A HK05101511A HK1068886A1 HK 1068886 A1 HK1068886 A1 HK 1068886A1 HK 05101511 A HK05101511 A HK 05101511A HK 05101511 A HK05101511 A HK 05101511A HK 1068886 A1 HK1068886 A1 HK 1068886A1
Authority
HK
Hong Kong
Prior art keywords
sup
kinase inhibitors
protein kinase
derivatives useful
indolinone derivatives
Prior art date
Application number
HK05101511A
Other languages
English (en)
Inventor
John H Griffin
Roger Briesewitz
Jonathan W Wray
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of HK1068886A1 publication Critical patent/HK1068886A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK05101511A 2001-12-27 2005-02-23 Indolinone derivatives useful as protein kinase inhibitors HK1068886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34374601P 2001-12-27 2001-12-27
US34381301P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1068886A1 true HK1068886A1 (en) 2005-05-06

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05101511A HK1068886A1 (en) 2001-12-27 2005-02-23 Indolinone derivatives useful as protein kinase inhibitors

Country Status (22)

Country Link
US (3) US6686362B2 (ko)
EP (1) EP1458713B1 (ko)
JP (1) JP4363985B2 (ko)
KR (1) KR100965519B1 (ko)
CN (1) CN1290844C (ko)
AT (1) ATE302771T1 (ko)
AU (1) AU2002360753B2 (ko)
BR (1) BR0215360A (ko)
CA (1) CA2470480C (ko)
CO (1) CO5611126A2 (ko)
DE (1) DE60205776T2 (ko)
DK (1) DK1458713T3 (ko)
ES (1) ES2247411T3 (ko)
HK (1) HK1068886A1 (ko)
HU (1) HUP0500111A3 (ko)
IL (1) IL162203A0 (ko)
MX (1) MXPA04006271A (ko)
NO (1) NO327550B1 (ko)
NZ (1) NZ533219A (ko)
PL (1) PL208283B1 (ko)
RU (1) RU2316554C2 (ko)
WO (1) WO2003057690A1 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US7105563B2 (en) * 2003-10-24 2006-09-12 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
JP2009511628A (ja) 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
US7414050B2 (en) 2006-04-20 2008-08-19 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2649739C (en) 2006-04-20 2015-09-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
ES2539170T3 (es) 2010-01-12 2015-06-26 Ab Science Inhibidores de quinasas de oxazol
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
KR20180074792A (ko) 2016-11-02 2018-07-03 아로그 파마슈티칼스, 인코퍼레이티드 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2429573T3 (es) 1998-05-29 2013-11-15 Sugen, Inc. Derivado de 2-indolinona sustituido por un pirrol como inhibidor de proteína kinasa
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1212318B1 (de) 1999-08-27 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte indolinone als tyrosinkinase inhibitoren
DE60014130T2 (de) 1999-10-06 2006-03-09 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
WO2001042243A2 (en) 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
NZ520640A (en) 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
JP5073147B2 (ja) 2000-08-18 2012-11-14 ミレニアム ファーマシューティカルズ インク． キナーゼインヒビターとしてのキナゾリン誘導体
EP1349852A2 (en) 2000-12-20 2003-10-08 Sugen, Inc. 4-(hetero)aryl substituted indolinones
US7195876B2 (en) 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Also Published As

Publication number Publication date
US6686362B2 (en) 2004-02-03
CO5611126A2 (es) 2006-02-28
DE60205776D1 (en) 2005-09-29
ATE302771T1 (de) 2005-09-15
US20040198804A1 (en) 2004-10-07
DK1458713T3 (da) 2005-10-31
US7223783B2 (en) 2007-05-29
JP2005514420A (ja) 2005-05-19
ES2247411T3 (es) 2006-03-01
US20030171378A1 (en) 2003-09-11
NO20042926L (no) 2004-07-08
CN1608063A (zh) 2005-04-20
WO2003057690A1 (en) 2003-07-17
JP4363985B2 (ja) 2009-11-11
NZ533219A (en) 2005-10-28
RU2316554C2 (ru) 2008-02-10
DE60205776T2 (de) 2006-06-14
EP1458713B1 (en) 2005-08-24
PL369602A1 (en) 2005-05-02
KR100965519B1 (ko) 2010-06-23
IL162203A0 (en) 2005-11-20
HUP0500111A2 (hu) 2005-07-28
KR20040070283A (ko) 2004-08-06
AU2002360753B2 (en) 2008-08-21
BR0215360A (pt) 2004-12-14
US7060703B2 (en) 2006-06-13
CA2470480A1 (en) 2003-07-17
HUP0500111A3 (en) 2009-10-28
RU2004122918A (ru) 2005-03-27
EP1458713A1 (en) 2004-09-22
AU2002360753A1 (en) 2003-07-24
CN1290844C (zh) 2006-12-20
PL208283B1 (pl) 2011-04-29
MXPA04006271A (es) 2004-10-04
CA2470480C (en) 2010-12-14
NO327550B1 (no) 2009-08-10
US20060142281A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
HK1068886A1 (en) Indolinone derivatives useful as protein kinase inhibitors
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
AU2464601A (en) Tricyclic protein kinase inhibitors
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
PL367682A1 (en) Dolastatin 10 derivatives
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
MX2008002104A (es) Derivados de 1-acildihidropirazol.
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
AU2002366563A1 (en) Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
DE60203740D1 (de) Luminacine analoge und deren verwendung

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111220